ArticleNature2022
Prolonged viral suppression with anti-HIV-1 antibody therapy.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05612178 (A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy), which is not on this map. Cited by 148 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05612178 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation
A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Who cites it
148 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.Journal of the International AIDS Society · 2024Pooled it
- VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.Science translational medicine · 2026Trial
- Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.BMC infectious diseases · 2026Trial
- Trial
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.The Journal of infectious diseases · 2025Trial
- Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data.Journal of the International AIDS Society · 2025Trial
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.The lancet. HIV · 2024Trial
- Trial
- Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.Science translational medicine · 2023Trial
- Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.Nature medicine · 2022Trial
- Article
- Autologous and broadly neutralizing antibodies drive ART-free HIV control.Nature medicine · 2026Article
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- CD8ɑ+ cells suppress SIV replication without the development of mutations within MHC class-I-restricted epitopes during post-treatment control.Journal of virology · 2026Article
- HIV cure after HCT: 7 horses seem to be on the mark.Blood advances · 2026Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 8 institutions in 1 country.
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7295-8128
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Elina StoffelLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Gaëlle BretonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Katrina G MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2247-3178
Martina TurrojaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-9640-0559
Allison ButlerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7353-3420
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jacqueline D ReevesLabcorp-Monogram Biosciences, LabCorp, South San Francisco, CA, USA.
Christos J PetroupoulosLabcorp-Monogram Biosciences, LabCorp, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5496-8090
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Caroline S JiangCenter for Clinical and Translational Science, The Rockefeller University, New York, NY, USA.
Nikolaus JilgDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9154-2769
Johannes F ScheidDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Rajesh GandhiDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Michael C SnellerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Anthony FauciLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5153-7340
Marina Caskey *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.ORCID http://orcid.org/0000-0003-1727-8693
Michel C Nussenzweig *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.ORCID http://orcid.org/0000-0003-0592-8564
Rockefeller University · USMassachusetts General Hospital · USNational Institutes of Health · USLabCorp (United States) · USBeth Israel Deaconess Medical Center · USColumbia University Irving Medical Center · USHoward Hughes Medical Institute · USRagon Institute of MGH, MIT and Harvard · US
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CRISPIN, MAX · 2012 to 2018
$131.5MStuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MREACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9MRole of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MOptimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoirU01AI129825 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2017 to 2021
$4.0MRelevance of Resistance Mutations for the Susceptibility to Broadly Neutralizing Antibodies Against HIV-1K08AI155173 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JILG, NIKOLAUS · 2021 to 2024
$798kHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS K08 AI155173NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS U01 AI129825NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164565
Abstract
HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is effective but requires lifelong drug administration owing to a stable reservoir of latent proviruses integrated into the genome of CD4
Indexed as
Anti-Retroviral AgentsHIV-1HIV AntibodiesHIV InfectionsViral LoadCD4-Positive T-LymphocytesHumansProvirusesViremiaVirus LatencyAnti-Retroviral AgentsHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05612178ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.